Natixis Advisors’s Pacira BioSciences PCRX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$578K	Buy	25,556 +13,569	+113%	+$302K	﹤0.01%	1509
2025 Q4	$310K	Sell	11,987 -4,125	-26%	-$98.1K	﹤0.01%	1545
2025 Q3	$415K	Buy	16,112 +2,905	+22%	+$71.4K	﹤0.01%	1536
2025 Q2	$316K	Buy	13,207 +68	+0.5%	+$1.71K	﹤0.01%	1541
2025 Q1	$327K	Buy	+13,139	New	+$315K	﹤0.01%	1534
2024 Q3	–	Sell	-11,413	Closed	-$327K	–	1632
2024 Q2	$327K	Sell	11,413 -404	-3%	-$11.5K	﹤0.01%	1509
2024 Q1	$345K	Buy	+11,817	New	+$363K	﹤0.01%	1454
2023 Q3	–	Sell	-11,993	Closed	-$481K	–	1518
2023 Q2	$481K	Buy	11,993 +1,638	+16%	+$67.7K	﹤0.01%	1344
2023 Q1	$423K	Buy	+10,355	New	+$412K	﹤0.01%	1354
2022 Q4	–	Sell	-12,515	Closed	-$666K	–	1498
2022 Q3	$666K	Buy	+12,515	New	+$696K	﹤0.01%	1211
2022 Q2	–	Sell	-12,898	Closed	-$984K	–	1494
2022 Q1	$984K	Buy	12,898 +2,381	+23%	+$159K	﹤0.01%	1137
2021 Q4	$633K	Buy	+10,517	New	+$580K	﹤0.01%	1203
2020 Q4	–	Sell	-38,528	Closed	-$2.32M	–	1237
2020 Q3	$2.32M	Buy	38,528 +1,894	+5%	+$110K	0.01%	752
2020 Q2	$1.92M	Buy	36,634 +15,228	+71%	+$636K	0.01%	813
2020 Q1	$718K	Buy	+21,406	New	+$889K	0.01%	980